Document is current
Any future updates will be listed below
-
Authors
Iacobucci, Ilaria
Zeng, Andy G. X. https://orcid.org/0000-0002-3223-6400
Gao, Qingsong
Garcia-Prat, Laura
Baviskar, Pradyumna https://orcid.org/0000-0003-1110-5695
Shah, Sayyam
Murison, Alex
Voisin, Veronique
Chan-Seng-Yue, Michelle https://orcid.org/0000-0003-3773-9354
Cheng, Cheng
Qu, Chunxu
Bailey, Colin
Lear, Matthew https://orcid.org/0000-0002-9767-2115
Witkowski, Matthew T. https://orcid.org/0000-0003-1434-4288
Zhou, Xin https://orcid.org/0000-0003-3979-8200
Zaldivar Peraza, Airen
Gangwani, Karishma https://orcid.org/0000-0002-2986-4481
Advani, Anjali S.
Luger, Selina M.
Litzow, Mark R. https://orcid.org/0000-0002-9816-6302
Rowe, Jacob M.
Paietta, Elisabeth M.
Stock, Wendy
Dick, John E. https://orcid.org/0000-0002-9527-8317
Mullighan, Charles G. https://orcid.org/0000-0002-1871-1850
- License Information
-
More Information
Article History
Received: 24 December 2023
Accepted: 24 April 2025
First Online: 27 June 2025
Competing interests
: I.I. reports consultation honoraria from Arima and travel expenses reimbursed by Mission Bio and Takara for invited talks. C.G.M. received research funding from AbbVie and Pfizer, honoraria from Amgen and Illumina, and royalty payments from Cyrus. He is on an advisory board for Illumina. J.E.D. received research funding from BMS/Celgene and intellectual property licenses from Pfizer/Trillium Therapeutics. A.S.A. reported advisory board membership for Nkarta, Pfizer, Novartis and Jazz Pharmaceuticals; honoraria from KSA, PER, MD Education, ALF Medscape/Global Activity, Web med, Onc live AML Geronimo; steering committee membership for Glycomimetics; and royalty payments from Springer. The other authors declare no competing interests.
